3 Programs

  • Exploring the Potential Role of PROTAC Estrogen Receptor Degraders in the Management of HR-Positive Metastatic Breast Cancer

    Explore program
    • October 2025 1.25 ABIM MOC, ABS MOC 58min
      • E
      Erika Hamilton
    • October 2025 0.75 ABIM MOC, ABS MOC 29min
      • E
      Erika Hamilton
  • Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer: Impact of Biomarkers and Existing Comorbidities

    Explore program
    • April 2025 1.25 ABIM MOC, ABS MOC, CME 53min
      • A
      Adam M Brufsky
    • April 2025 0.75 ABIM MOC, ABS MOC, CME 32min
      • A
      Adam M Brufsky
  • Optimizing the Selection of First-Line Therapy for Patients with Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement

    Explore program
    • April 2025 1.25 ABIM MOC, ABS MOC, CME 57min
      • J
        Justin F Gainor, MD
      Justin F Gainor
    • April 2025 0.75 ABIM MOC, ABS MOC, CME 31min
      • J
        Justin F Gainor, MD
      Justin F Gainor